ReviewNature reviews. Immunology2002
New hope for an AIDS vaccine.
Review in Nature reviews. Immunology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers.Vaccine · 2008Trial
- Examining psychological correlates of vaccine hesitancy: a comparative study between the US and Israel.Frontiers in public health · 2024Article
- New therapeutic vaccination strategies for the treatment of chronic hepatitis B.Virologica Sinica · 2014Review
- Impact of ETIF deletion on safety and immunogenicity of equine herpesvirus type 1-vectored vaccines.Journal of virology · 2010Article
- Exploring peptide mimics for the production of antibodies against discontinuous protein epitopes.Molecular immunology · 2010Article
- Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck.Hepatitis research and treatment · 2010Article
- Article
- Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge.Vaccine · 2009Article
- A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.Immunology letters · 2009Article
- DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory.AIDS research and human retroviruses · 2008Article
- Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization.Journal of virology · 2007Article
- Immunological analysis of a Lactococcus lactis-based DNA vaccine expressing HIV gp120.Genetic vaccines and therapy · 2007Article
- Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.Journal of virology · 2005Article
- DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.Journal of virology · 2005Article
- T cell vaccines for microbial infections.Nature medicine · 2005Review
- C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences.Current HIV research · 2005Article
- Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2.Journal of virology · 2005Article
- Article
- Nonviral DNA vectors for immunization and therapy: design and methods for their obtention.Journal of molecular medicine (Berlin, Germany) · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The twenty-first century has begun with considerable success for new AIDS vaccines in macaque models. A common feature of these vaccines is their ability to induce high-frequency CD8+ T-cell responses that control, rather than prevent, infection with HIV. The new vaccines, which include DNA vaccines and live viral vectors, are based on technologies that have been developed since the start of the AIDS epidemic. The ultimate promise of these vaccines will be realized only when efficacy trials in humans are conducted.
Indexed as
Identifiers
12001995What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.